Dr Reddy’s gains on launch of Vigabatrin powder

The company launched Vigabatrin powder in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) powder, approved by the US Food and Drug Administration (USFDA).

The Dr Reddy’s Laboratories’ stock gained more than a percent intraday on August 20 after the company launched Vigabatrin powder (oral solution).

The company launched Vigabatrin powder in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) powder, approved by the US Food and Drug Administration (USFDA).

At 11:01 hours, the stock was quoting Rs 2,539.60, up Rs 29.10, or 1.16 percent on the BSE.